Classification of pulmonary hypertension for md exams 10 marks answer from fishman and murray only combined structured
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have all the material I need from both Fishman and Murray. Let me compile the comprehensive structured answer.
Classification of Pulmonary Hypertension
Sources: Fishman's Pulmonary Diseases and Disorders, 5e (Table 72-1, Ch. 72) | Murray & Nadel's Textbook of Respiratory Medicine, 7e (Tables 83.1, 83.2, Ch. 83)
I. DEFINITION
Murray & Nadel (Table 83.1): The 6th World Symposium on Pulmonary Hypertension (WSPH) defines PH as a mean pulmonary artery pressure (mPAP) > 20 mm Hg, measured by right heart catheterization (RHC). The previous threshold of 25 mm Hg was arbitrary; the new cut-off of 20 mm Hg represents two standard deviations above the mean in healthy individuals (normal mPAP = 14 ± 3.3 mm Hg).
II. HEMODYNAMIC CLASSIFICATION (Murray & Nadel, Table 83.1)
Based on PCWP (pulmonary capillary wedge pressure) and PVR (pulmonary vascular resistance in Wood units):
| Category | mPAP | PCWP | PVR | WHO Groups |
|---|---|---|---|---|
| Normal | 14 ± 3.3 mm Hg | 8 ± 2.9 mm Hg | 0.93 ± 0.38 WU | - |
| Precapillary PH | > 20 mm Hg | ≤ 15 mm Hg | ≥ 3 WU | 1, 3, 4, 5 |
| Isolated postcapillary PH | > 20 mm Hg | > 15 mm Hg | < 3 WU | 2 and 5 |
| Combined pre- and postcapillary PH | > 20 mm Hg | > 15 mm Hg | ≥ 3 WU | 2 and 5 |
mPAP = mean pulmonary artery pressure; PCWP = pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; WU = Wood units
III. WHO/WSPH CLINICAL CLASSIFICATION - 5 GROUPS
(Fishman, Table 72-1; Murray & Nadel, Table 83.2 - both citing Simonneau et al., Eur Respir J. 2019)
GROUP 1: PULMONARY ARTERIAL HYPERTENSION (PAH)
All subtypes share the common histopathologic finding of arterial remodeling and inflammation with increased PVR. PAH is defined hemodynamically as: mPAP ≥ 20 mm Hg + PCWP ≤ 15 mm Hg + PVR ≥ 3 WU, in the absence of other causes.
- 1.1 Idiopathic PAH (IPAH) - No identifiable cause; replaces old term "primary pulmonary hypertension" (PPH). Represents ~50% of PAH.
- 1.2 Heritable PAH - Genetic mutations (BMPR2 most common - seen in ~80% of familial and ~20% of sporadic cases; also ACVRL1, ENG, SMAD9, CAV1, KCNK3, TBX4, ATP13A3, SOX17, GDF2/BMP9)
- 1.3 Drug and toxin induced - e.g., aminorex, fenfluramine, dexfenfluramine, toxic rapeseed oil, benfluorex, methamphetamine
- 1.4 Associated with:
- 1.4.1 Connective tissue disease (largest subgroup ~25%; scleroderma most common)
- 1.4.2 HIV infection (~0.5% prevalence; pathology indistinguishable from IPAH)
- 1.4.3 Portal hypertension (portopulmonary hypertension)
- 1.4.4 Congenital heart diseases (e.g., Eisenmenger syndrome)
- 1.4.5 Schistosomiasis
- 1.5 PAH long-term responders to calcium channel blockers (new category, 6th WSPH) - Unique clinical characteristics; vasoreactivity testing positive
- 1.6 PAH with overt features of venous/capillary involvement - Pulmonary veno-occlusive disease (PVOD) / Pulmonary capillary hemangiomatosis (PCH) (venous pathology in addition to arterial)
- 1.7 Persistent pulmonary hypertension of the newborn (PPHN) syndrome
Fishman note: The term "secondary pulmonary hypertension" is deliberately abandoned - it inappropriately suggested clinical similarity among conditions as different as COPD and congenital heart disease, and masked important similarities between IPAH and associated forms (e.g., Eisenmenger, HIV-PAH).
GROUP 2: PH DUE TO LEFT HEART DISEASE
Hemodynamic hallmark: postcapillary PH (elevated PCWP > 15 mm Hg). Most common form of PH overall.
- 2.1 PH due to heart failure with preserved LVEF (HFpEF)
- 2.2 PH due to heart failure with reduced LVEF (HFrEF)
- 2.3 Valvular heart disease (especially mitral stenosis, mitral regurgitation)
- 2.4 Congenital/acquired cardiovascular conditions leading to postcapillary PH
Passive elevation of mPAP driven by obstruction to pulmonary venous outflow (Fishman's "passive" mechanism). Can progress to combined pre- and postcapillary PH with remodeling.
GROUP 3: PH DUE TO LUNG DISEASES AND/OR HYPOXIA
Hemodynamic hallmark: precapillary PH. Pathogenesis involves both vasoconstrictive (chronic hypoxia) and obliterative (parenchymal fibrosis) mechanisms (Fishman).
- 3.1 Obstructive pulmonary disease (COPD, emphysema)
- 3.2 Restrictive lung disease (ILD, e.g., IPF, scleroderma-ILD)
- 3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
- 3.4 Hypoxia without lung disease (e.g., high altitude, sleep apnea, hypoventilation syndromes)
- 3.5 Developmental lung disorders
GROUP 4: PH DUE TO PULMONARY ARTERY OBSTRUCTIONS (formerly CTEPH)
Hemodynamic hallmark: precapillary PH. The only potentially curable form of PH (pulmonary endarterectomy).
- 4.1 Chronic thromboembolic PH (CTEPH) - Most important subtype; often under-recognized
- 4.2 Other pulmonary artery obstructions:
- 4.2.1 Sarcoma (high- or intermediate-grade) or angiosarcoma
- 4.2.2 Other malignant tumors (renal carcinoma, uterine carcinoma, germ cell tumors of the testis)
- 4.2.3 Non-malignant tumors (e.g., uterine leiomyoma)
- 4.2.4 Arteritis without connective tissue disease
- 4.2.5 Congenital pulmonary artery stenoses
- 4.2.6 Parasites (e.g., hydatidosis)
Murray: CTEPH represents a larger population than PAH and may be more common than previously recognized. Linked to Fishman's "obstructive" pathogenic mechanism.
GROUP 5: PH WITH UNCLEAR AND/OR MULTIFACTORIAL MECHANISMS
A heterogeneous group; multiple pathogenic mechanisms. Hemodynamically can be precapillary, postcapillary, or combined.
- 5.1 Hematologic disorders: chronic hemolytic anemia (sickle cell disease, thalassemia), myeloproliferative disorders
- 5.2 Systemic and metabolic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, Gaucher disease, glycogen storage diseases, neurofibromatosis
- 5.3 Others: chronic renal failure with or without hemodialysis; fibrosing mediastinitis
- 5.4 Complex congenital heart disease:
- Segmental PH: isolated pulmonary artery of ductal origin, absent pulmonary artery, pulmonary atresia with VSD and major aortopulmonary collateral arteries (MAPCAs), hemitruncus
- Single ventricle: unoperated or operated (post-Fontan)
- Scimitar syndrome
IV. PATHOGENIC MECHANISMS OF PH (Fishman, Table 72-2)
Fishman conceptualizes 6 pathogenic mechanisms underlying PH, with each correlating to clinical groups:
| Mechanism | Pathophysiology | Clinical Correlate |
|---|---|---|
| Passive | Obstruction to pulmonary venous outflow | Group 2 (left heart disease, mitral stenosis) |
| Hyperkinetic | Abnormally high pulmonary blood flow | Group 1.4.4 (congenital heart disease with L-to-R shunt) |
| Obstructive | Pulmonary thromboembolic disease | Group 4 (CTEPH) |
| Obliterative | Destruction of pulmonary vascular bed by parenchymal disease | Group 3 (ILD, fibrosis) |
| Vasoconstrictive | Hypoxic vasoconstriction | Group 3 (COPD, high altitude) |
| Idiopathic | No discernible cause | Group 1.1 (IPAH) |
V. WHO FUNCTIONAL CLASSIFICATION OF PH
(Referenced in both Fishman and Murray; based on NYHA functional classification)
| Class | Description |
|---|---|
| Class I | PH without limitation of physical activity; ordinary activity does not cause dyspnea, fatigue, chest pain, or near-syncope |
| Class II | Slight limitation; comfortable at rest; ordinary activity causes dyspnea, fatigue, chest pain, or near-syncope |
| Class III | Marked limitation; comfortable at rest; less-than-ordinary activity causes dyspnea, fatigue, chest pain, or near-syncope |
| Class IV | Unable to perform any physical activity; dyspnea and/or fatigue at rest; signs of right heart failure present |
Most patients with IPAH at diagnosis are WHO functional class III or IV (Fishman, Ch. 72).
VI. KEY EXAM POINTS (Combined Fishman + Murray)
- Threshold change: mPAP > 20 mm Hg (not 25 mm Hg) per 6th WSPH (Murray).
- PAH = Group 1 only - defined by precapillary hemodynamics (mPAP > 20, PCWP ≤ 15, PVR ≥ 3 WU).
- Most common form of PH overall = Group 2 (left heart disease), not PAH (Murray, Fig. 83.1).
- BMPR2 mutation = most common genetic cause of heritable PAH (~80% of familial cases) - Fishman.
- New in 6th WSPH: Category 1.5 (CCB long-term responders); Group 4 renamed from "CTEPH" to broader "PH due to pulmonary artery obstructions."
- CTEPH (Group 4) = only potentially surgically curable form of PH via pulmonary endarterectomy.
- "Primary PH" and "secondary PH" are obsolete terms - deliberately replaced by the 5-group classification (Fishman).
- Group 1.6 (PVOD/PCH) = includes venous pathology, hence positioned within Group 1 but distinct from pure arterial PAH (Murray).
Fishman's Pulmonary Diseases and Disorders (5e), Table 72-1, Ch. 72 (Kim, Mandel, Smith, Yuan) | Murray & Nadel's Textbook of Respiratory Medicine (7e), Tables 83.1 & 83.2, Ch. 83
This is a shared conversation. Sign in to Orris to start your own chat.